TY - JOUR
T1 - Natalizumab in the pediatric MS population
T2 - Results of the Italian registry
AU - Ghezzi, Angelo
AU - Moiola, Lucia
AU - Pozzilli, Carlo
AU - Brescia-Morra, Vincenzo
AU - Gallo, Paolo
AU - Grimaldi, Luigi Maria Edoardo
AU - Filippi, Massimo
AU - G., Giancarlo Comi
PY - 2015/9/25
Y1 - 2015/9/25
N2 - Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on this topic. Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before 18 years of age. Results: 101 patients were included (69 females), mean age of MS onset 12.9±2.7 years, mean age at NA initiation 14.7±2.4 years. Mean treatment duration was 34.2±18.3 months. During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3±1.0 in the year prior to NA and decreased to 0.1±0.3 (p
AB - Background: Natalizumab is a promising option for pediatric multiple sclerosis (MS) patients with active evolution and a poor response to Interferon-beta or Glatiramer Acetate. However, no data are available in large cohorts of patients and after a long-term follow up. Our study was planned to shed lights on this topic. Methods: A registry was established in 2007 in Italy to collect MS cases treated with Natalizumab (NA) before 18 years of age. Results: 101 patients were included (69 females), mean age of MS onset 12.9±2.7 years, mean age at NA initiation 14.7±2.4 years. Mean treatment duration was 34.2±18.3 months. During NA treatment, a total of 15 relapses were recorded in 9 patients, annualized relapse rate was 2.3±1.0 in the year prior to NA and decreased to 0.1±0.3 (p
UR - http://www.scopus.com/inward/record.url?scp=84942155555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942155555&partnerID=8YFLogxK
U2 - 10.1186/s12883-015-0433-y
DO - 10.1186/s12883-015-0433-y
M3 - Article
AN - SCOPUS:84942155555
VL - 15
JO - BMC Neurology
JF - BMC Neurology
SN - 1471-2377
IS - 1
M1 - 174
ER -